Sep 11, 2023 / 08:15PM GMT
Unidentified Participant
Good afternoon. I have to disclose the research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Good afternoon, Jas. Great to have you here. And it's been a year since you've been in front of the audience, at least at the Morgan Stanley conference. And there's been incredible progress at the company. Before we dive into the specific programs, perhaps you can just give a very brief overview in Keros and your vision for the company.
Jas Seehra - Keros Therapeutics, Inc. - CEO
Thank you, Jessica. It's wonderful to be given this opportunity a year later. I think for us, the vision has always been to be a commercial company. And we're progressing towards that, with 050, our lead product candidate, progressing through the Phase 2 trial. And we're now looking forward to
Keros Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers